In this edition we dare to dream – fever dream, no less – about the future of the NHS. We go beyond the current chaos and ...

Sonoma Biotherapeutics has announced positive interim results from its ongoing phase 1 Regulate-RA trial evaluating ...

The Cell and Gene Therapy Catapult (CGT Catapult) has published its latest annual review, highlighting the vital role of ...

Alys Pharmaceuticals has announced the dosing of the first subject in its phase 1/1b trial of ALY-301, a first-in-class mast cell selective c-Kit inhibitor developed for the treatment of Cold ...

Domain Therapeutics has announced the first patients have been dosed in its phase 1/2 DOMISOL clinical trial of DT-7012, a ...

Qureight’s Vascul8 model has been validated in a peer-reviewed study marking a significant advance in the treatment of ...

ProImmune has announced the launch of its ProVE SL Self-Loading MHC Class I Monomers, a new reagent platform designed to enhance antigen-specific CD8+ T cell detection. The Oxford-based life science ...

Evotec SE has announced a $25m milestone payment from Bristol Myers Squibb, recognising scientific progress made within their ...

ENA Respiratory has raised US$22.4m (AU$34m) in Series B financing to support the phase 2 clinical development of its nasal ...

Incyte has announced promising new data from its phase 3b TRuE-AD4 trial of Opzelura (ruxolitinib cream) in adults with moderate atopic dermatitis (AD), revealing significant improvements in clinical ...

Nxera Pharma and its partner Cancer Research UK have presented encouraging results from the completed phase 1 portion of ...

The Global Fund has welcomed a £6 million joint investment from GSK and ViiV Healthcare to strengthen community-led responses ...